| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | SLAM family member 8, B-lymphocyte activator macrophage expressed, BCM-like membrane protein, CD353, SLAMF8, BLAME |
| Entrez GeneID | 56833 |
| WB Predicted band size | 31.7kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This SLAMF8 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 256-285 amino acids from the C-terminal region of human SLAMF8. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于SLAMF8抗体的模拟参考文献示例(仅供参考，实际文献需通过学术数据库验证)：
---
1. **文献名称**: *SLAMF8 regulates inflammatory responses in macrophages by modulating NF-κB signaling*
**作者**: Kumar R, et al.
**摘要**: 本研究探讨了SLAMF8抗体在巨噬细胞炎症反应中的作用，发现阻断SLAMF8可抑制NF-κB通路的激活，从而减少促炎细胞因子(如TNF-α、IL-6)的释放，提示其在治疗慢性炎症疾病中的潜力。
2. **文献名称**: *Targeting SLAMF8 with monoclonal antibodies enhances antitumor immunity in murine models*
**作者**: Wang Y, et al.
**摘要**: 通过小鼠肿瘤模型研究，发现抗SLAMF8抗体能够增强CD8+ T细胞的肿瘤浸润和活性，抑制肿瘤生长，表明SLAMF8可能是癌症免疫治疗的新靶点。
3. **文献名称**: *SLAMF8 as a checkpoint molecule in autoimmune disorders: Insights from antibody blockade experiments*
**作者**: Lee S, et al.
**摘要**: 研究显示，SLAMF8在自身免疫性疾病患者的抗原呈递细胞中高表达。使用特异性抗体阻断SLAMF8可减轻实验性自身免疫性脑脊髓炎(EAE)模型的症状，机制涉及调节树突细胞的耐受性。
4. **文献名称**: *The role of SLAMF8 in phagosome maturation and bacterial clearance*
**作者**: Martinez J, et al.
**摘要**: 本文揭示了SLAMF8抗体通过影响吞噬体成熟过程，增强巨噬细胞对胞内病原体(如结核杆菌)的清除能力，为抗感染治疗提供了新方向。
---
**注意**：以上为模拟示例，实际文献需通过PubMed、Web of Science等平台检索(关键词：SLAMF8、CD353、抗体治疗)。建议优先参考近年发表的综述或高影响力期刊论文(如*Nature Immunology*、*Cell Reports*)。
SLAMF8 (Signaling Lymphocyte Activation Molecule Family Member 8), also known as CD353 or BLAME, is a cell surface receptor belonging to the SLAM family of immune regulatory receptors. Primarily expressed on immune cells such as macrophages, dendritic cells, and activated lymphocytes, SLAMF8 plays a role in modulating immune responses through its engagement with signaling adaptors like SAP (SLAM-associated protein). Structurally, it contains immunoreceptor tyrosine-based switch motifs (ITSMs) that mediate intracellular signaling, influencing cell activation, differentiation, and cytokine production.
Research highlights SLAMF8's involvement in both innate and adaptive immunity. It regulates phagocytic functions in macrophages and modulates inflammatory responses, potentially contributing to autoimmune diseases, chronic inflammation, and cancer. In cancer microenvironments, SLAMF8 expression on tumor-associated macrophages (TAMs) has been linked to immunosuppressive phenotypes, promoting tumor progression. Conversely, its role in autoimmune conditions like lupus or rheumatoid arthritis remains under investigation, with studies suggesting it may either exacerbate or dampen pathology depending on context.
SLAMF8-targeting antibodies are emerging as therapeutic tools. Blocking antibodies aim to disrupt pro-tumorigenic signaling in cancers, while agonist antibodies might enhance immune activation in chronic infections. Challenges include understanding its dual roles in different diseases and optimizing antibody specificity to avoid off-target effects. Current preclinical studies focus on elucidating signaling mechanisms and validating SLAMF8 as a biomarker or therapeutic target, positioning it as a promising candidate for immune-modulating therapies.
×
